Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
Abstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Metho...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-07855-z |
id |
doaj-f23e5aea9d2541eabd13f5f28e5e79c2 |
---|---|
record_format |
Article |
spelling |
doaj-f23e5aea9d2541eabd13f5f28e5e79c22021-02-07T12:50:05ZengBMCBMC Cancer1471-24072021-02-012111710.1186/s12885-021-07855-zComparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysisDechuang Jiao0Jingyang Zhang1Jiujun Zhu2Xuhui Guo3Yue Yang4Hui Xiao5Zhenzhen Liu6Department of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of breast disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalAbstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Methods Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. Results Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). Conclusions Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients.https://doi.org/10.1186/s12885-021-07855-zInflammatory breast cancer (IBC); breast Cancer-specific survival (BCSS); survival rate; survival analysis; |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dechuang Jiao Jingyang Zhang Jiujun Zhu Xuhui Guo Yue Yang Hui Xiao Zhenzhen Liu |
spellingShingle |
Dechuang Jiao Jingyang Zhang Jiujun Zhu Xuhui Guo Yue Yang Hui Xiao Zhenzhen Liu Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis BMC Cancer Inflammatory breast cancer (IBC); breast Cancer-specific survival (BCSS); survival rate; survival analysis; |
author_facet |
Dechuang Jiao Jingyang Zhang Jiujun Zhu Xuhui Guo Yue Yang Hui Xiao Zhenzhen Liu |
author_sort |
Dechuang Jiao |
title |
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_short |
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_full |
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_fullStr |
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_full_unstemmed |
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_sort |
comparison of survival in non-metastatic inflammatory and other t4 breast cancers: a seer population-based analysis |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-02-01 |
description |
Abstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Methods Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. Results Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). Conclusions Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients. |
topic |
Inflammatory breast cancer (IBC); breast Cancer-specific survival (BCSS); survival rate; survival analysis; |
url |
https://doi.org/10.1186/s12885-021-07855-z |
work_keys_str_mv |
AT dechuangjiao comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT jingyangzhang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT jiujunzhu comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT xuhuiguo comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT yueyang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT huixiao comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT zhenzhenliu comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis |
_version_ |
1724280696467357696 |